You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ADC

Showing 1 - 25 of 1,252
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

RC48-ADC in Breast Cancer

Not yet recruiting
  • Breast Cancer
  • Disitamab vedotin
  • (no location specified)
Apr 30, 2023

Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)

Not yet recruiting
  • Gastric Cancer
  • Beijing, China
    Beijing Cancer Hospital
Aug 7, 2023

Advanced Breast Cancer Trial (Disitamab vedotin)

Not yet recruiting
  • Advanced Breast Cancer
  • Disitamab vedotin
  • (no location specified)
Apr 16, 2023

Non-muscle Invasive Bladder Cancer Trial in Chengdu (RC48-ADC)

Not yet recruiting
  • Non-muscle Invasive Bladder Cancer
  • Chengdu, Sichuan, China
    West China Hospital
Aug 10, 2023

NMIBC Trial in Beijing (RC48-ADC in Combination with gemcitabine)

Recruiting
  • NMIBC
  • RC48-ADC in Combination with gemcitabine
  • Beijing, Beijing, China
    Peking University First Hosptital
Jul 10, 2023

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Oct 6, 2023

Colorectal Cancer Trial in Hangzhou (RC48-ADC plus Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • RC48-ADC plus Bevacizumab
  • Hangzhou, Zhejinag, China
    The second affiliated hospital of Zhejiang University
Mar 24, 2023

Metastatic Castration-resistant Prostate Cancer Trial (Disitamab Vedotin(RC48-ADC))

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Disitamab Vedotin（RC48-ADC）
  • (no location specified)
Jul 13, 2023

Carcinoma, Upper Tract Urothelial Carcinoma, UTUC Trial in Nanjing (RC48-ADC and JS001)

Recruiting
  • Carcinoma
  • +2 more
  • RC48-ADC and JS001
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Jun 15, 2023

NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Feb 16, 2023

Solid Tumor Trial (Disitamab vedotin)

Not yet recruiting
  • Solid Tumor
  • Disitamab vedotin
  • (no location specified)
Jul 10, 2023

Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

Not yet recruiting
  • Triple-negative Breast Cancer
  • A1: SHR-A1811
  • +11 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2023

Solid Tumor Trial in United States (TR1801-ADC)

Active, not recruiting
  • Unspecified Adult Solid Tumor, Protocol Specific
  • TR1801-ADC
  • Los Angeles, California
  • +4 more
Oct 30, 2022

HIV Vaccine Trial in São Paulo (Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides, Alpha-type-1

Not yet recruiting
  • HIV Vaccine
  • Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
  • +2 more
  • São Paulo, Brazil
    Hospital das Clínicas da Faculdade de Medicina da USP
Mar 14, 2023

HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER2-low Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

Gastric Cancer Trial in Beijing (RC48-ADC, RC98-ADC)

Not yet recruiting
  • Gastric Cancer
  • Beijing, Beijing, China
    Remegen
Aug 21, 2022

Advanced Solid Tumor Trial (HLX43)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Oct 30, 2023

Advanced Gastroesophageal Adenocarcinoma Trial in Beijing (RC48-ADC, S-1)

Recruiting
  • Advanced Gastroesophageal Adenocarcinoma
  • Beijing, China
  • +2 more
Sep 14, 2022

Biliary Tract Cancer Trial (RC48-ADC, Envafolimab)

Not yet recruiting
  • Biliary Tract Cancer
  • (no location specified)
Jun 9, 2022

Solid Tumor Trial (18F-FDG)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Jul 18, 2022

Cervical Cancer Trial in China (Disitamab Vedotin, Zimberelimab)

Not yet recruiting
  • Cervical Cancer
  • Bengbu, Anhui, China
  • +11 more
Nov 23, 2023

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

Brain Mapping Trial run by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Brain connectivity and physiology,

Completed
  • Brain Mapping
  • Brain connectivity and physiology
  • Brain Wave
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 18, 2022

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, JS001)

Not yet recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, Beijing, China
  • +2 more
Apr 2, 2022